𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Splenic artery embolization for the treatment of refractory ascites after liver transplantation

✍ Scribed by Cristiano Quintini; Giuseppe D'Amico; Chase Brown; Federico Aucejo; Koji Hashimoto; Dympna M. Kelly; Bijan Eghtesad; Mark Sands; John J. Fung; Charles M. Miller


Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
283 KB
Volume
17
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

✦ Synopsis


Refractory ascites (RA) is a challenging complication after orthotopic liver transplantation. Its treatment consists of the removal of the precipitating factors. When the etiology is unknown, supportive treatment can be attempted. In severe cases, transjugular intrahepatic portosystemic shunts, portocaval shunts, and liver retransplantation have been used with marginal results. Recently, splenic artery embolization (SAE) has been described as an effective procedure for reducing portal hyperperfusion in patients undergoing partial or whole liver transplantation. Here we describe our experience with SAE for the treatment of RA. Between June 2004 and June 2010, 6 patients underwent proximal SAE for RA. Intraoperative flow measurements, graft characteristics, embolization portal vein (PV) velocities before and after SAE, and spleen/liver volume ratios were collected and analyzed. The response to treatment was assessed with imaging (ultrasound/computed tomography) and on the basis of clinical outcomes (weight changes, diuretic requirements, and the time to ascites resolution). The PV velocity decreased significantly for each patient after the embolization (median ΒΌ 66.5 cm/second before SAE and median ΒΌ 27.5 cm/second after SAE, P < 0.01). All patients experienced a significant postprocedural weight loss (mean ΒΌ 88.1 6 28.4 kg before SAE and mean ΒΌ 75.8 6 28.4 kg after SAE, P < 0.01) and a dramatic decrease in their diuretic requirements. All but 1 of the patients experienced a complete resolution of ascites after a median time of 49.5 days (range ΒΌ 12-295 days). No patient presented with postembolization complications. In conclusion, SAE was effective in reducing the PV velocity immediately after the procedure. Clinically, this translated into a dramatic weight loss, a reduction of diuretic use, and a resolution of ascites. SAE appears to be a safe and effective treatment for RA.


πŸ“œ SIMILAR VOLUMES


Delayed splenic artery occlusion for tre
✍ Abhinav Humar; Joy Beissel; Shaina Crotteau; Melissa Cohen; John Lake; William D πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 170 KB πŸ‘ 1 views

We looked at the impact of delayed splenic artery occlusion (SAO) on recipients with established small-for-size syndrome (SFSS) after partial graft liver transplantation [either from a living donor (LD) or split from a deceased donor (DD)]. Between 1999 and 2007 we performed a total of 100 partial l

Use of splenic artery embolization to re
✍ Charissa Y. Chang; Ashwani K. Singal; Sri V. Ganeshan; Thomas D. Schiano; Robert πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 374 KB πŸ‘ 1 views

Recurrent venous thrombosis following liver transplantation for Budd-Chiari syndrome is common, particularly in the setting of an underlying myeloproliferative disorder. We describe a patient who developed refractory ascites due to portal vein thrombosis following liver transplantation for Budd-Chia

Antiviral treatment of recurrent hepatit
✍ Didier Samuel πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 56 KB πŸ‘ 1 views

## H epatitis C virus (HCV)-related cirrhosis is currently the leading indication for liver transplantation in Europe and in the United States. 1,2 HCV recurrence after transplantation is almost universal, and 60%-90% of patients will develop lesions of chronic hepatitis C on the graft. 3 The cour

Rifaximin for the treatment of recurrent
✍ Guy Neff; Victoria Zacharias; Tiffany E. Kaiser; Amy Gaddis; Nyingi Kemmer πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 211 KB πŸ‘ 1 views

Previous data have suggested that the nonsystemic antibiotic rifaximin may be effective for the treatment of Clostridium difficile infection (CDI). This single-center retrospective study evaluated the efficacy of rifaximin for the treatment of CDI refractory to standard treatments in patients who ha

Nifedipine versus carvedilol in the trea
✍ Alessandra Galioto; Andrea Semplicini; Giacomo Zanus; Silvano Fasolato; Antoniet πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 159 KB πŸ‘ 1 views

The aim of this study was to compare nifedipine and carvedilol in the treatment of de novo arterial hypertension after orthotopic liver transplantation (OLT). The study included 50 patients who developed arterial hypertension after OLT. Twenty-five patients received nifedipine (group A), and 25 rece